|
|
Iqvia Holdings Inc (NYSE: IQV) |
|
Price: $179.3500
$-0.67 
-0.372%
|
| Day's High:
| $179.665
| Week Perf:
| -3.52 %
|
| Day's Low: |
$ 177.15 |
30 Day Perf: |
-6.07 % |
| Volume (M): |
43 |
52 Wk High: |
$ 253.84 |
| Volume (M$): |
$ 7,744 |
52 Wk Avg: |
$217.72 |
| Open: |
$180.27 |
52 Wk Low: |
$177.15 |
|
|
| Market Capitalization (Millions $) |
32,877 |
| Shares
Outstanding (Millions) |
183 |
| Employees |
53,000 |
| Revenues (TTM) (Millions $) |
15,405 |
| Net Income (TTM) (Millions $) |
1,373 |
| Cash Flow (TTM) (Millions $) |
326 |
| Capital Exp. (TTM) (Millions $) |
602 |
Iqvia Holdings Inc
IQVIA Holdings Inc. Overview
IQVIA Holdings Inc. is a prominent global provider of innovative solutions and services tailored to the biopharmaceutical and healthcare industries. The company was established through the merger of two key players in the industry: Quintiles, well-regarded for its clinical research capabilities, and IMS Health, known for its expertise in healthcare data and analytics. The firms headquarters are located in Durham, North Carolina, and it operates in over 100 countries worldwide.
Core Services and Expertise
IQVIA is recognized as a leading provider of clinical trial services. Its offerings encompass:
- Clinical Research and Development: Comprehensive support for the phases of drug development.
- Clinical Trial Execution: Efficient management and execution of trials to ensure compliance and quality.
- Data Management: Robust systems for collecting, managing, and analyzing clinical data.
- Patient Recruitment: Strategic approaches to identify and enroll participants effectively for clinical trials.
Alongside clinical services, IQVIA provides a variety of commercial solutions, including:
- Market Research: Insights into market dynamics and consumer behavior.
- Sales and Marketing Effectiveness: Strategies and tools to enhance the effectiveness of sales and marketing efforts.
- Commercial Operations: Comprehensive support for the operational side of product commercialization.
Data Assets and Insights
IQVIA boasts an extensive portfolio of proprietary data assets, including one of the largest healthcare databases globally, which encompasses over 1 billion patient records. This extensive data enables IQVIA to deliver critical insights into healthcare trends, identify suitable patient populations for clinical studies, and assist clients in making informed decisions surrounding product development and market entry.
Clientele
The companys diverse client base includes:
- Pharmaceutical and biotechnology companies
- Medical device manufacturers
- Healthcare providers
- Payers (insurance companies)
- Government agencies
IQVIA collaborates closely with these clients to help them devise and implement innovative solutions that improve healthcare outcomes.
Corporate Social Responsibility
Beyond its core business, IQVIA actively engages in several social responsibility initiatives. These include:
- Addressing health disparities
- Promoting diversity and inclusion within the workplace
- Supporting underserved communities across the globe
Through these initiatives, the company aims to make a meaningful impact on public health and healthcare equity.
Workforce and Culture
IQVIA employs around 67,000 professionals, many of whom are highly skilled in various domains, including science, clinical practice, and data analysis. The companys workplace culture emphasizes innovation, collaboration, and continuous learning, ensuring that employees are well-equipped with the necessary skills and resources to contribute positively to healthcare globally. IQVIA is dedicated to developing its workforce while fostering an environment that encourages growth and professional development.
In summary, IQVIA Holdings Inc. stands out as a vital player in the healthcare landscape, combining extensive data resources and clinical expertise to support the advancement of biopharmaceutical innovations and healthcare solutions worldwide.
Company Address: 2400 Ellis Rd. Durham 27703 NC
Company Phone Number: 998-2000 Stock Exchange / Ticker: NYSE IQV
|
|
|
Customers Net Income grew by |
IQV's Customers Net Profit Margin grew to |
88.29 % |
10.65 %
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Business Update
Published Mon, Feb 24 2025 7:30 PM UTC
IQVIA s AI Innovations: A Dominant Force in Healthcare and Life SciencesIQVIA (NYSE:IQV), a global leader in delivering advanced analytics, technology solutions, and clinical research services, has recently garnered significant industry recognition with its breakthrough artificial intelligence (AI) technologies across multiple fronts. The Research Triangle Park-based compan...
|
| Economy
Published Wed, Oct 2 2024 3:47 PM UTC
In a landscape where technology and healthcare converge, IQVIA Holdings Inc. has taken a significant step forward with the introduction of its new generative AI technology, the IQVIA AI Assistant. This innovative tool aims to revolutionize how life science customers obtain and interpret essential insights, underlining IQVIA?s commitment to enhancing clinical research and hea...
|
| Business Update
Published Thu, Jul 11 2024 2:56 PM UTC
IQVIA Leads the Way in Medical Affairs and Regulatory Operations, According to Independent Research Firm RESEARCH TRIANGLE PARK, N.C. - IQVIA (NYSE:IQV), a global healthcare intelligence company, has once again demonstrated its industry leadership by being recognized as a Leader in the Life Sciences Regulatory and Medical Affairs Operations PEAK Matrix Assessment 2024 survey...
|
| Business Update
Published Tue, Jun 25 2024 12:47 PM UTC
IQVIA s AI Triumph: Navigating Growth Amidst Industry Contraction In a significant development for the life sciences industry, IQVIA Holdings Inc. (NYSE:IQV) has earned the Best Use of Artificial Intelligence in Healthcare accolade at the 8th Annual MedTech Breakthrough Awards for its SmartSolve Enterprise Quality Management System (eQMS). This recognition underscores IQVIA ...
|
| Iqvia Holdings Inc
an avid investor and financial observer, I closely followed the recent financial results announced by IQVIA Holdings Inc. With a focus on providing advanced analytics, technology solutions, and clinical research services to the life sciences industry, IQVIA reported moderate revenue elevation of 2.327% to $3.74 billion in the fiscal span ending March 31, 2024. Furthermore, profitability grew moderately by 1.96% to $1.56 year-on-year.
IQVIA's performance in the first quarter of 2024 earnings season demonstrated a slight dip, with revenue decreasing by -3.387% from $3.87 billion in the preceding period. Income also saw a decline of -39.43%, falling from $2.58 per share. However, despite the decrease in net profits from $289.000 million to $288.000 million, this only represents a minimal drop of -0.35% in the corresponding period a year before.
|
| Per Share |
Current |
| Earnings (TTM) |
7.51 $ |
| Revenues (TTM) |
84.04 $
|
| Cash Flow (TTM) |
1.78 $ |
| Cash |
10.05 $
|
| Book Value |
33.1 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
7.51 $
|
| Revenues (TTM) |
84.04 $ |
| Cash Flow (TTM) |
1.78 $ |
| Cash |
10.05 $
|
| Book Value |
33.1 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| Americas |
|
 47.18 % |
of total Revenue |
| Europe and Africa |
|
33.03 % |
of total Revenue |
| Asia-Pacific |
|
19.79 % |
of total Revenue |
| Technology Analytics Solutions |
|
39.89 % |
of total Revenue |
| Technology Analytics Solutions Americas |
|
20.46 % |
of total Revenue |
| Technology Analytics Solutions Europe and Africa |
|
16.07 % |
of total Revenue |
| Technology Analytics Solutions Asia-Pacific |
|
3.36 % |
of total Revenue |
| Research Development Solutions |
|
55.49 % |
of total Revenue |
| Research Development Solutions Americas |
|
24.87 % |
of total Revenue |
| Research Development Solutions Europe and Africa |
|
15.58 % |
of total Revenue |
| Research Development Solutions Asia-Pacific |
|
15.04 % |
of total Revenue |
| Contract Sales Medical Solutions |
|
4.62 % |
of total Revenue |
| Contract Sales Medical Solutions Americas |
|
1.85 % |
of total Revenue |
| Contract Sales Medical Solutions Europe and Africa |
|
1.39 % |
of total Revenue |
| Contract Sales Medical Solutions Asia-Pacific |
|
1.39 % |
of total Revenue |
| |
On February 6 2025 the Iqvia Holdings Inc provided following guidance
nnIQVIA Holdings Inc. Reports Q4 and Full-Year 2024 Financial Results; Reiterates 2025 Projectionsnn
Research Triangle Park, N.C. ? February 6, 2025 ? IQVIA Holdings Inc. (NYSE: IQV), a premier global provider of advanced clinical research services, commercial insights, and healthcare analytical tools in the life sciences sector, announced its financial outcomes for the fourth quarter and the complete year of 2024.
Ari Bousbib, the Chairman and CEO of IQVIA, expressed confidence in the company?s performance, stating, We are pleased to report strong results for the fourth quarter, marking a successful conclusion to 2024. He highlighted that revenue from Research and Development Solutions (R...
|
|
|
1.69%